ASLAN004 is a fully human monoclonal antibody that targets the IL-13 receptor α1 subunit, or IL-13Rα1, with potential to be a best-in-class therapy. ASLAN004 is currently in Phase 1 development. By targeting IL-13Rα1, ASLAN004 potently inhibits signaling of both interleukin 4, or IL-4, and interleukin 13, or IL-13. IL-4 and IL-13 are central to triggering symptoms of allergy in atopic dermatitis, such as redness and itching of the skin, as well as asthma symptoms such as shortness of breath, wheezing and coughing.
Dupilumab is marketed for severe atopic dermatitis and asthma. As we target the same pathways as dupilumab, we believe ASLAN004 can follow a similar regulatory path. We believe ASLAN004 has the potential to become a first-in-class IL-13Rα1 inhibitor. By targeting IL-13Rα1, a receptor with a narrower cellular distribution than the IL-4 receptor, we believe ASLAN004 has the potential to offer both a lower dose and lower dosing frequency, which are important features for subcutaneous injections, providing greater patient convenience. In addition, ASLAN004 has more selective binding than dupilumab, which we believe could give ASLAN004 a more favourable side effect profile than dupilumab. ASLAN has initiated a Phase 1 clinical trial investigating ASLAN004 as a therapeutic antibody for atopic dermatitis. A Single Ascending Dose (SAD) clinical trial in healthy volunteers was completed in 2Q 2019. In October 2019, we initiated a Multiple Ascending Dose (MAD) clinical trial in moderate-to-severe atopic dermatitis patients. We expect to release interim data in 2H 2020, with completion expected 1H 2021.
In the future, ASLAN may also develop ASLAN004 in other inflammatory indications, such as chronic obstructive pulmonary disorder, or COPD. We licensed worldwide rights for ASLAN004 from CSL in May 2014.
CSL (ASX:CSL) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since 1916, CSL has been driven by the promise to save lives using the latest technologies. Today, CSL — including its two businesses, CSL Behring and Seqirus – provides life-saving products to more than 60 countries and employs nearly 20,000 people.
To learn more about CSL, please visit www.csl.com